Research programme: lysosomal storage disorder therapeutics - M6P Therapeutics
Latest Information Update: 15 Feb 2022
Price :
$50 *
At a glance
- Originator M6P Therapeutics
- Class Enzymes; Gene therapies
- Mechanism of Action Enzyme replacements; Gene transference
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Research Neuronal ceroid lipofuscinosis
Most Recent Events
- 10 Feb 2022 Pharmacodynamics data from preclinical trial presented at the 18th Annual WORLDSymposium™ (Annual WORLDSymposium-2022)
- 08 Oct 2021 Early research in Neuronal ceroid lipofuscinosis in USA (unspecified route) before October 2021
- 08 Oct 2021 Pharmacodynamics data from preclinical trials in Neuronal ceroid lipofuscinosis released by M6P Therapeutics